Bradley H. Strauss

Showing 1-9 of 9 articles

The use of ultrasound-stimulated contrast agents as an adjuvant for collagenase therapy in chronic total occlusions

Thind A, Strauss B, Karshafian R, Teitelbaum A, Ladouceur M, Akbar M, Rosen B, Bohnen M, Whyne C, Goertz D, Foster S

August 19, 2014 | 10.4244/EIJV10I4A82

Unexpected calcification after direct intravascular injection of autologous bone marrow-derived cells in a chronic total occlusion model

Nili N, Lim S, Qiang B, Qi X, Weisbrod M, Ladouceur-Wodzak M, Gofine N, Berk T, Saperia J, Wright G, Strauss B

July 21, 2014 | 10.4244/EIJV10I3A56

Relationship between initial treatment strategy and quality of life in patients with coronary chronic total occlusions

Wijeysundera H, Norris C, Fefer P, Galbraith P, Knudtson M, Wolff R, Wright G, Strauss B, Ko D

February 20, 2014 | 10.4244/EIJV9I10A197

A novel lead attenuator to reduce operator exposure to scattered radiation in transradial coronary procedures

Osherov A, Seidelin P, Wolff R, Wright G, Strauss B, Robert N

October 25, 2013 | 10.4244/EIJV9I6A121

Therapeutic angiogenesis with VEGF164 for facilitation of guidewire crossing in experimental arterial chronic total occlusions

Teitelbaum A, Qi X, Osherov A, Fraser A, Ladouceur-Wodzak M, Munce N, Qiang B, Weisbrod M, Bierstone D, Erlich I, Sparkes J, Wright G, Strauss B

January 18, 2013 | 10.4244/EIJV8I9A165

Characterisation of a novel porcine coronary artery CTO model

Fefer P, Robert N, Qiang B, Liu G, Munce N, Anderson K, Osherov A, Ladouceur-Wodzak M, Qi X, Dick A, Weisbrod M, Samuel M, Butany J, Wright G, Strauss B

April 20, 2012 | 10.4244/EIJV7I12A225

Climbing PCI success rates in complex chronic total occlusions: joining “The Club”

Fefer P, Strauss B

August 30, 2011 | 10.4244/EIJV7I4A69

A novel method for the measurement of proximal fibrous cap puncture force in chronic total occlusions: the effect of increasing age

Thind A, Strauss B, Teitelbaum A, Karshafian R, Ladouceur M, Whyne C, Goertz D, Foster S

March 21, 2011

A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan

Segev A, Nili N, Osherov A, Qiang B, Wong A, Pillarisetti S, Strauss B

May 25, 2010

1

Latest news

Lipid-rich plaque density and LDL-C in statin-treated vs statin-naïve patients

FREE ARTICLE - Rebecca Torguson et al.

January 17, 2022

Redo transcatheter mitral valve replacement in mitral annular calcification

FREE ARTICLE - Jennifer Jdaidani et al

January 13, 2022

EuroCTO Club Consensus on Dual Lumen Microcatheters for CTO Recanalisation; Predicting Radial Crossover in ACS, the MATRIX score; DAPT duration for BRS; and more…

December 17, 2021

TAVI vs SAVR in bicuspid aortic valve stenosis

FREE ARTICLE - Monil Majmundar et al.

January 12, 2022

Management of MR patients undergoing TMVI screening

FREE ARTICLE - Sebastian Ludwig et al.

January 7, 2022

Outcomes in patients with ACS treated with the NeVa stent

FREE ARTICLE - Alessandro Spirito et al.

January 7, 2022

Two-year outcomes from SORT OUT IX trial

FREE ARTICLE - Julia Ellert-Gregersen et al.

January 5, 2022

Valvular disease